for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allogene Therapeutics Inc

ALLO.OQ

Latest Trade

27.37USD

Change

-0.41(-1.48%)

Volume

88,548

Today's Range

26.85

 - 

27.75

52 Week Range

22.20

 - 

35.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
27.78
Open
27.62
Volume
88,548
3M AVG Volume
8.15
Today's High
27.75
Today's Low
26.85
52 Week High
35.55
52 Week Low
22.20
Shares Out (MIL)
121.75
Market Cap (MIL)
3,382.19
Forward P/E
-14.32
Dividend (Yield %)
--

Latest Developments

More

Allogene Therapeutics Reports Second Quarter 2019 Financial Results

Allogene Therapeutics Reports Q1 Loss Per Share Of $0.32

Allogene Therapeutics Reports Q4, FY2018 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Industry

Biotechnology & Drugs

Contact Info

210 E Grand Ave

+1.650.4572700

http://www.allogene.com/

Executive Leadership

Arie S. Belldegrun

Executive Chairman of the Board, Co-Founder

David Chang

President, Chief Executive Officer, Co-Founder, Director

Joshua A. Kazam

Co-Founder, Director

Eric T. Schmidt

Chief Financial Officer

Alison Moore

Chief Technical Officer

Key Stats

2.00 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-7.310

2019(E)

-1.940
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-35.38
Return on Equity (TTM)
-33.26

Latest News

Latest News

BUZZ-U.S. STOCKS ON THE MOVE-Eventbrite, oil stocks, Big Lots, Exxon Mobil, Costco

* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were on pace for their fifth day of losses on Friday, after weak U.S. jobs data in February added...

UPDATE 1-Moderna, largest biotech to go public, fails to impress in market debut

Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions.

Moderna, largest biotech to go public, fails to impress in market debut

Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in the U.S. markets spurred by investors fretting over an economic slowdown.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up